Histopathological characterization of ProMisE molecular groups of endometrial cancer

被引:75
作者
Raffone, Antonio [1 ]
Travaglino, Antonio [2 ]
Mascolo, Massimo [2 ]
Carotenuto, Consolata [1 ]
Guida, Maurizio [1 ]
Mollo, Antonio [3 ]
Insabato, Luigi [2 ]
Zullo, Fulvio [1 ]
机构
[1] Univ Naples Federico II, Sch Med, Dept Neurosci Reprod Sci & Dent, Gynecol & Obstet Unit, Naples, Italy
[2] Univ Naples Federico II, Sch Med, Dept Adv Biomed Sci, Anat Pathol Unit, Via Sergio Pansini 5, I-80131 Naples, Italy
[3] Univ Salerno, Dept Med Surg & Dent, Gynecol & Obstet Unit, Scuola Med Salernitana, Baronissi, SA, Italy
关键词
Prognosis; Treatment; Endometrium; Risk assessment; Tumor; Carcinoma; DIAGNOSIS;
D O I
10.1016/j.ygyno.2020.01.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. After the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) development, endometrial cancer (EC) may be reclassified in four novel prognostic groups: POLE-mutated (POLE-mt), mismatch-repair-deficient (MMR-d), p53-abnormal (p53abn), p53-wild-type (p53wt). However, histopathological characteristics of each ProMisE group are still undefined. Such characterization may be useful to understand how this novel molecular classifier may change the current patient management, reducing over- and undertreatment. Aim. To provide a histopathological characterization of ProMisE groups of EC, in terms of histological grade (G3 vs G12), histotype, lymphovascular space invasion (LVSI), deep myometrial invasion (>50%), lymph node involvement, and European Society for Medical Oncology (ESMO) risk category. Materials and methods. A systematic review and meta-analysis was performed by searching seven electronic databases from their inception to May 2019, for studies that reported histopathological characteristics of each ProMisE group. Pooled prevalence of each histopathological characteristic of EC in each ProMisE group was calculated. Results. Four studies with 1171 patients were included in the systematic review, out of which three studies with 912 patients were included in the meta-analysis. Pooled prevalence estimates were: - in the MMR-d group, G3 = 47.4%, G12 = 52.6%; endometrioid = 85.8%, non-endometrioid = 14.2%; LVSI-present = 41.3%, -absent = 58.7%; deep myometrial invasion-present = 44.5%, -absent = 55.5%; lymph node involvement-present = 9.9%, -absent = 90.1%; low-risk = 30.1%, intermediate risk = 19.9%, high-risk = 50%; - in the POLE-mt group, G3 = 39.6%, G12 = 60.4%; endometrioid = 86.1%, non-endometrioid = 13.9%; LVSI-present = 32.7%, -absent = 67.3%; deep myometrial invasion-present = 27.3%, -absent = 72.7%; lymph node involvement-present = 0%, -absent = 100%; low-risk = 44.1%, intermediate-risk = 22.5%, high-risk = 33.4%; - in the p53-wt group, G3 = 15.6%, G12 = 84.4%; endometrioid = 96.7%, non-endometrioid = 3.3%; LVSI-present = 13.8%, -absent = 86.2%; deep myometrial invasion-present = 27.4%, -absent = 72.6%; lymph node involvement-present = 4.3%, -absent = 95.7%; low-risk = 59.5%, intermediate-risk = 17.3%, high-risk = 23.2%; - in the p53-abn group, G3 = 90%, G12 = 10%; endometrioid = 27%, non-endometrioid = 73%; LVSI-present = 48.8%, -absent = 51.2%; deep myometrial invasion-present = 48.9%, -absent = 51.1%; lymph node involvement-present = 23.7%, -absent = 76.3%; low-risk = 7.2%, intermediate-risk = 8.1%, high-risk = 84.7%. Conclusions. The histopathological characterization of the ProMisE groups suggests that many patients are currently undertreated or overtreated (especially in the POLE-mt and MMR-d groups) (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:252 / 259
页数:8
相关论文
共 41 条
[31]  
Travaglino A., 2019, AM J CLIN PATHOL, DOI [10.1093/ajcp/aqz132Aug21., DOI 10.1093/AJCP/AQZ132AUG21]
[32]   Clear cell endometrial carcinoma and the TCGA classification [J].
Travaglino, Antonio ;
Raffone, Antonio ;
Mascolo, Massimo ;
Guida, Maurizio ;
Insabato, Luigi ;
Zannoni, Gian F. ;
Zullo, Fulvio .
HISTOPATHOLOGY, 2020, 76 (02) :336-338
[33]   Nuclear expression of β-catenin in endometrial hyperplasia as marker of premalignancy [J].
Travaglino, Antonio ;
Raffone, Antonio ;
Saccone, Gabriele ;
Mascolo, Massimo ;
D'Alessandro, Pietro ;
Arduino, Bruno ;
Mollo, Antonio ;
Insabato, Luigi ;
Zullo, Fulvio .
APMIS, 2019, 127 (11) :699-709
[34]   Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia [J].
Travaglino, Antonio ;
Raffone, Antonio ;
Saccone, Gabriele ;
Mollo, Antonio ;
De Placido, Giuseppe ;
Mascolo, Massimo ;
Insabato, Luigi ;
Zullo, Fulvio .
APMIS, 2019, 127 (06) :427-434
[35]   PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? [J].
Travaglino, Antonio ;
Raffone, Antonio ;
Saccone, Gabriele ;
Mascolo, Massimo ;
Pignatiello, Sara ;
Mollo, Antonio ;
De Placido, Giuseppe ;
Insabato, Luigi ;
Zullo, Fulvio .
APMIS, 2019, 127 (04) :161-169
[36]   Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review [J].
Travaglino, Antonio ;
Raffone, Antonio ;
Saccone, Gabriele ;
Insabato, Luigi ;
Mollo, Antonio ;
De Placido, Giuseppe ;
Zullo, Fulvio .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2019, 98 (09) :1086-1099
[37]   Immunohistochemical Nuclear Expression of -Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer [J].
Travaglino, Antonio ;
Raffone, Antonio ;
Saccone, Gabriele ;
De Luca, Caterina ;
Mollo, Antonio ;
Mascolo, Massimo ;
De Placido, Giuseppe ;
Insabato, Luigi ;
Zullo, Fulvio .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2019, 151 (05) :529-538
[38]   Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria [J].
Travaglino, Antonio ;
Raffone, Antonio ;
Saccone, Gabriele ;
Mollo, Antonio ;
De Placido, Giuseppe ;
Insabato, Luigi ;
Zullo, Fulvio .
HISTOPATHOLOGY, 2019, 74 (05) :676-687
[39]   PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis [J].
Travaglino, Antonio ;
Raffone, Antonio ;
Saccone, Gabriele ;
Insabato, Luigi ;
Mollo, Antonio ;
De Placido, Giuseppe ;
Zullo, Fulvio .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2018, 231 :104-110
[40]   Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: A specific marker of precancer and novel indication for treatment A systematic review and meta-analysis [J].
Travaglino, Antonio ;
Raffone, Antonio ;
Saccone, Gabriele ;
Insabato, Luigi ;
Mollo, Antonio ;
De Placido, Giuseppe ;
Zullo, Fulvio .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2018, 97 (12) :1415-1426